Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy

Muscle and Nerve

Volumn 43, Issue 1, 2011, Pages 94-102

  Gilliam, Laura A A ^a   Moylan, Jennifer S ^a   Callahan, Leigh Ann ^b   Sumandea, Marius P ^a   Reid, Michael B ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chemotherapy; Inflammation; Oxidative stress; Respiratory muscle; Weakness

Indexed keywords

DOXORUBICIN; 3 NITROTYROSINE; 4 HYDROXYNONENAL; ACTIN; DESMIN; MYOSIN LIGHT CHAIN; TROPOMYOSIN; TROPONIN; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIAPHRAGM MOVEMENT; DIAPHRAGM MUSCLE; MALE; MOUSE; MUSCLE FIBER CONTRACTION; MUSCLE FORCE; MUSCLE FUNCTION; MUSCLE INJURY; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE INFLAMMATION; BREATHING MUSCLE; C57BL 6 MOUSE; DIAPHRAGM DISEASE; DIAPHRAGM INJURY; INFLAMMATION; MURINE MODEL; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; MUSCLE TETANIC CONTRACTION; MUSCLE TWITCH; OXIDATIVE STRESS; RESPIRATION DEPRESSION; SARCOLEMMA; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DIAPHRAGM; DISEASE MODELS, ANIMAL; DOXORUBICIN; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; MUSCLE WEAKNESS; RESPIRATORY PARALYSIS;

EID: 78650493654     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21809     Document Type: Article

References (45)

1. Elbl L, Vasova I, Tomaskova I, Jedlicka F, Kral Z, Navratil M, et al. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leuk Lymphoma 2006;47:843-851.
2. Okuyama T, Akechi T, Kugaya A, Okamura H, Imoto S, Nakano T, et al. Factors correlated with fatigue in disease-free breast cancer patients: application of the cancer fatigue scale. Support Care Cancer 2000;8:215-222.
3. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021-2031.
4. Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol 2008;104:57-66.
5. Chu E, De Nita VT. Physician's cancer chemotherapy drug manual. Sudbury, MA: Jones & Bartlett; 2008.
6. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P, Hardman JG, et al. Goodman & Gilman's the pharmacologic basis of therapeutics. New York: McGraw-Hill; 2001.
7. Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer. Curr Opin Obstet Gynecol 2009;21:15-24.
8. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 2009;63:799-805.
9. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999;79:1479-1486.
10. Anderson NJ, Hacker ED. Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors. Clin J Oncol Nurs 2008;12:445-454.
11. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-611.
12. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 2006;23:127-139.
13. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986;261:3060-3067.
14. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007;7:147-156.
15. Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, Lancel S. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 2009;388:727-731.
16. Supinski GS, Callahan LA. Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol 2007;102:2056-2063.
17. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994;372:546-548.
18. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 2009;107:1935-1942.
19. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-244.
20. Close RI. Dynamic properties of mammalian skeletal muscles. Physiol Rev 1972;52:129-197.
21. Reid MB, Haack KE, Franchek KM, Valberg PA, Kobzik L, West MS. Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue in vitro. J Appl Physiol 1992;73:1797-1804.
22. McMullen CA, Andrade FH. Contractile dysfunction and altered metabolic profile of the aging rat thyroarytenoid muscle. J Appl Physiol 2006;100:602-608.
23. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995;118:959-964.
24. Thomas LB, Joseph GL, Adkins TD, Andrade FH, Stemple JC. Laryngeal muscles are spared in the dystrophin deficient mdx mouse. J Speech Lang Hear Res 2008;51:586-595.
25. Solaro RJ, Pang DC, Briggs FN. The purification of cardiac myofibrils with Triton X-100. Biochim Biophys Acta 1971;245:259-262.
26. Bottone AE, Voest EE, de Beer EL. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment. Clin Cancer Res 1998;4:1031-1037.
27. de Beer EL, Bottone AE, van der Velden J, Voest EE. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol 2000;57:1152-1157.
28. Doroshow JH, Tallent C, Schechter JE. Ultrastructural features of adriamycin-induced skeletal and cardiac muscle toxicity. Am J Pathol 1985;118:288-297.
29. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med 2002;166:479-484.
30. Lawler JM, Hu Z. Interaction of nitric oxide and reactive oxygen species on rat diaphragm contractility. Acta Physiol Scand 2000;169:229-236.
31. Andrade FH, Reid MB, Allen DG, Westerblad H. Effect of hydrogen peroxide and dithiothreitol on contractile function of single skeletal muscle fibres from the mouse. J Physiol Online 1998;509:565-575.
32. Wirtschafter JD, McLoon LK. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 1998;105:342-346.
33. McLoon LK, Falkenberg JH, Dykstra D, Iaizzo PA. Doxorubicin chemomyectomy as a treatment for cervical dystonia: histological assessment after direct injection into the sternocleidomastoid muscle. Muscle Nerve 1998;21:1457-1464.
34. Mathy-Hartert M, Bourgeois E, Grulke S, Deby-Dupont G, Caudron I, Deby C, et al. Purification of myeloperoxidase from equine polymorphonuclear leucocytes. Can J Vet Res 1998;62:127-132.
35. Prochniewicz E, Lowe DA, Spakowicz DJ, Higgins L, O'Conor K, Thompson LV, et al. Functional, structural, and chemical changes in myosin associated with hydrogen peroxide treatment of skeletal muscle fibers. Am J Physiol Cell Physiol 2008;294: C613-C626.
36. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev 2001;81:209-237.
37. Paulin D, Li Z. Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res 2004;301:1-7.
38. Bonifati DM, Ori C, Rossi CR, Caira S, Fanin M, Angelini C. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 2000;46:517-522.
39. Janue A, Olive M, Ferrer I. Oxidative stress in desminopathies and myotilinopathies: a link between oxidative damage and abnormal protein aggregation. Brain Pathol 2007;17:377-388.
40. Ochala J. Thin filament proteins mutations associated with skeletal myopathies: defective regulation of muscle contraction. J Mol Med 2008;86:1197-1204.
41. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-844.
42. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-hydroxynonenal as a biological signal: molecular basis and pathophysiological implications. Antioxid Redox Signal 1999;1:255-284.
43. Kee AJ, Hardeman EC. Tropomyosins in skeletal muscle diseases. Adv Exp Med Biol 2008;644:143-157.
44. Hernandez OM, Jones M, Guzman G, Szczesna-Cordary D. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 2007;292: H1643-H1654.
45. Sarna L, Evangelista L, Tashkin D, Padilla G, Holmes C, Brecht ML, et al. Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer. Chest 2004;125:439-445.